Effects of oral antihyperglycemic agents on extracellular matrix synthesis by mesangial cells
- PMID: 9853263
- DOI: 10.1046/j.1523-1755.1998.00207.x
Effects of oral antihyperglycemic agents on extracellular matrix synthesis by mesangial cells
Abstract
Background: Increased expression of the glucose transporter GLUT1 in mesangial cells (MCs) markedly stimulates glucose transport and the formation of extracellular matrix (ECM), even when ambient glucose concentrations are low. Certain antihyperglycemic agents cause GLUT1 overexpression and increase glucose transport in various tissues. However, their effects on the kidney are unknown. Because diabetic glomerulosclerosis is characterized by the accumulation of mesangial matrix, was studied the effects of antihyperglycemic agents on matrix metabolism in MCs cultured either in 8 or 20 mM glucose.
Methods: Membrane-associated GLUT1 was measured by immunoblotting. The initial rate of glucose transport was determined according to the 2-deoxy-D[14C(U)]glucose uptake. Collagen metabolism was studied by metabolic radiolabeling with [14C]-proline. Fibronectin in the medium was measured by ELISA. GLUT1 mRNA was estimated by Northern analysis.
Results: The sulfonylurea tolazamide increased GLUT1 protein expression by 107 and 69% in 8 and 20 mM glucose-grown cells, respectively. However, GLUT1 mRNA levels remained unchanged. Transporter-dependent deoxyglucose uptake was increased by tolazamide up to 184% in a dose-dependent fashion and was evident at both glucose concentrations after three or five days of exposure to the drug. Tolazamide significantly stimulated transforming growth factor-beta 1 (TGF-beta 1) secretion and the total synthesis of collagen and collagen and fibronectin accumulation in the medium of MCs maintained in high or low glucose concentrations. The biguanide metformin did not alter GLUT1 expression, glucose transport, fibronectin formation, or collagen metabolism, except at high concentrations.
Conclusion: Tolazamide markedly enhances ECM synthesis and accumulation in MCs probably by stimulating GLUT1 expression, glucose transport and TGF-beta 1 secretion, irrespective of the ambient glucose concentration. This effect was dose-dependent and minimally inducible by metformin.
Similar articles
-
TGF-beta 1 stimulates glucose uptake by enhancing GLUT1 expression in mesangial cells.Kidney Int. 1999 May;55(5):1704-12. doi: 10.1046/j.1523-1755.1999.00438.x. Kidney Int. 1999. PMID: 10231432
-
[Regulation of the expression and function of glucose transporter-1 by TGF-beta 1 and high glucose in mesangial cells].Chin Med J (Engl). 2000 Jun;113(6):508-13. Chin Med J (Engl). 2000. PMID: 11775867 Chinese.
-
Glucose transporter in human glomerular mesangial cells modulated by transforming growth factor-beta and rhein.Acta Pharmacol Sin. 2001 Feb;22(2):169-75. Acta Pharmacol Sin. 2001. PMID: 11741523
-
Glucose transporters in diabetic nephropathy.Pediatr Nephrol. 2005 Apr;20(4):447-51. doi: 10.1007/s00467-004-1748-x. Epub 2005 Feb 17. Pediatr Nephrol. 2005. PMID: 15717166 Review.
-
GLUT1 regulation of the pro-sclerotic mediators of diabetic nephropathy.Am J Nephrol. 2013;38(1):39-49. doi: 10.1159/000351989. Epub 2013 Jun 26. Am J Nephrol. 2013. PMID: 23817135 Review.
Cited by
-
Glibenclamide induces collagen IV catabolism in high glucose-stimulated mesangial cells.Exp Diabetes Res. 2012;2012:183535. doi: 10.1155/2012/183535. Epub 2012 Sep 12. Exp Diabetes Res. 2012. PMID: 23008698 Free PMC article.
-
Anti-diabetic treatment regulates pro-fibrotic TGF-β serum levels in type 2 diabetics.Diabetol Metab Syndr. 2013 Aug 31;5(1):48. doi: 10.1186/1758-5996-5-48. Diabetol Metab Syndr. 2013. PMID: 24004910 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous